Immix Biopharma Inc (IMMX US)

Analysis

Health Care • United States

Immix Biopharma, Inc. operates as a clinical-stage biopharmaceutical company. The Company focuses on developing a novel class of tissue-specific therapeutics in oncology and inflammation to treat inflammatory bowel disease, including ulcerative colitis and crohn's diseases. Immix Biopharma serves customers in the United States.

Refresh

Company Presentation • 07 Oct 2026 20:00

Investor presentation

Company Presentation • 01 Sep 2026 20:00

Corporate presentation

Company Presentation • 11 Aug 2026 20:00

Corporate presentation

Company Presentation • 03 Jul 2026 19:00

Corporate presentation

Company Presentation • 17 Jun 2026 19:00

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00